Biomind Labs Provides Corporate Update - Seite 2

• A nasal formulation prototype was designed using a 5-MeO-DMT thermosensitive gel. Its production was optimized using an experimental design, showing positive drug mucosal membrane permeation through in vitro assays.
• A pending patent application is associated with this formulation.

BMND08: 5-MeO-DMT Sublingual Formulation

• Successful development of a 5-MeO-DMT sublingual formulation. An inexpensive formulation, easy to scale, non-invasive and painless, guaranteeing treatment adherence.
• This sublingual formulation offers several advantages, including rapid onset of action, high bioavailability, precise dosing, reduced gastrointestinal disturbances, and improved patient compliance. These benefits make BMND08 a valuable option for a wide range of patient populations.
• A Phase IIa clinical trial is being conducted, initial results have demonstrated remarkable safety, tolerability, and no toxicity profile of BMND08. These results signify a pivotal advancement in Biomind’s journey to provide a comprehensive solution that targets both cognitive decline and mental health disorders.

Micro/Nanoparticles Pharmaceutical Formulations

• Nano pharmaceutical formulations of DMT and 5-MeO-DMT that preserve their bioactivity suitable for oral administration have been designed.
• A pending patent application is associated with them.

Mescaline Preclinical Cell-based Assays

• The preclinical mutagenicity AMES test for mescaline has shown an excellent safety profile, the results confirmed that it is not mutagenic at high doses.
• As a promising anti-inflammatory compound, mescaline has shown a relevant profile through in vitro assays, showing that it has four times more potency as an anti-inflammatory than dexamethasone, reducing the production of IL-6.

Mescaline Sustainable Production

• Development of artificial bacteria strain capable of producing the proper intermediaries to obtain mescaline has been completed.
• The production process is easy to scale and easy to perform under Good Manufacturing practices (“GMP”).

Intellectual Property Portfolio

The Company has submitted more than 20 patent applications to major international patent offices, including the USTPO (“United States Patent and Trademark Office”), PCT (“Patent Cooperation Treaty”), and EPO (“European Patent Office”). These applications are based on eight priority documents, indicating a diverse and robust innovation pipeline. Importantly, some of these applications have already received highly promising written opinions, suggesting strong potential for securing valuable patents in the future. This signifies the Company's commitment to protecting its groundbreaking biotechnology inventions and ensuring its competitive edge in the industry.